Document is current

Article History

Accepted: 17 June 2025

First Online: 9 July 2025

Change Date: 6 September 2025

Change Type: Update

Change Details: The original online version of this article was revised to update Fig. 2 and correct the section level heads.

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: HWM has EGPA research funding from AstraZeneca via a grant award to SS.SS reports grant awards for EGPA from AstraZeneca, and Advisory services for EGPA for AstraZeneca and GSK; consulting fees from AstraZeneca, GSK, Chiesi, Sanofi, and Areteia; payments for educational events for EGPA from GSK and AstraZeneca; and the Steering Group for BSAR guidelines for ANCA associated vasculitis. SPM reports research funding from AstraZeneca, GSK, and Senya Therapeutics to his institution; consulting fees from Vifor, Alexion, and AstraZeneca; personal fees from Vifor; participation on a Data Safety Monitoring Board or Advisory Board for Obivas TSC (Roche sponsor); co-chair UKIVAS, and BSR Guidelines Group for ANCA vasculitis. The other authors declare that they have no conflict of interest.